CITIC RESOURCES (01205) will be suspended from trading starting from March 5th to await the release of insider information and necessary disclosures of transactions.

08:58 05/03/2026

China Everbright Resources (01205) announced that the trading of the company's shares on the main board of the Hong Kong Stock Exchange will be suspended from 9:00 am on March 5, 2026 (Thursday) to await the publication of an announcement in accordance with Chapter 14 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange regarding insider information and transactions that require disclosure.

CITIC RESOURCES (01205) announced that trading of the company's shares will be suspended on the Main Board of the Stock Exchange of Hong Kong Limited from 9:00 a.m. on Thursday, March 5, 2026, pending the announcement of inside information and transactions required to be disclosed according to Chapter 14 of the Listing Rules of the Stock Exchange of Hong Kong Limited.

HK Stock Market Move | CSTONE PHARMA-B(02616) rose by over 12%, the company's independently developed PD-1/VEGF/CTLA-4 triple antibody is expected to achieve a major breakthrough.

HK Stock Market Move | AKESO-B(09926) rose more than 6% in early trading as it collaborates with the US-based INOVIO in exploring innovative treatments for glioblastoma using new DNA drugs.

HK Stock Market Move | ANTENGENE-B(06996) rose by over 11%, reaching a nearly $1.2 billion authorization agreement with Usher.

HK Stock Market Move | CSTONE PHARMA-B(02616) rose by over 12%, the company's independently developed PD-1/VEGF/CTLA-4 triple antibody is expected to achieve a major breakthrough.

HK Stock Market Move | AKESO-B(09926) rose more than 6% in early trading as it collaborates with the US-based INOVIO in exploring innovative treatments for glioblastoma using new DNA drugs.

HK Stock Market Move | ANTENGENE-B(06996) rose by over 11%, reaching a nearly $1.2 billion authorization agreement with Usher.